Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00492401 · ClinicalTrials.gov registry record · Phase 2
Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00492401: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00492401 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00492401, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This phase II trial is studying how well decitabine works in treating patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing
Interventions
- GENETIC microarray analysis
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG decitabine
- OTHER high performance liquid chromatography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2007-05 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00492401
The ClinicalTrials.gov registry entry for NCT00492401 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which microarray analysis is the first listed.
NCT00492401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00492401 about?
NCT00492401 is a clinical study titled "Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia". This phase II trial is studying how well decitabine works in treating patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing
What is the current status of trial NCT00492401?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2007-05. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00492401?
The interventions under investigation include: microarray analysis (GENETIC), laboratory biomarker analysis (OTHER), pharmacological study (OTHER), decitabine (DRUG), high performance liquid chromatography (OTHER).
Who is sponsoring clinical trial NCT00492401?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.